262 related articles for article (PubMed ID: 33402398)
1. Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management.
Garvey DR; Chhabra G; Ndiaye MA; Ahmad N
Mol Cancer Ther; 2021 Apr; 20(4):632-640. PubMed ID: 33402398
[TBL] [Abstract][Full Text] [Related]
2. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review.
Shu Y; Liu Y; Bian S; Xie Z; Liao C
Mini Rev Med Chem; 2023; 23(1):67-79. PubMed ID: 35657046
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of targeting polo-like kinase 4.
Lei Q; Yu Q; Yang N; Xiao Z; Song C; Zhang R; Yang S; Liu Z; Deng H
Eur J Med Chem; 2024 Feb; 265():116115. PubMed ID: 38199166
[TBL] [Abstract][Full Text] [Related]
5. PLK4: a link between centriole biogenesis and cancer.
Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK
Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762
[TBL] [Abstract][Full Text] [Related]
6. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
7. PLK4: a promising target for cancer therapy.
Zhao Y; Wang X
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983
[TBL] [Abstract][Full Text] [Related]
8. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication.
Sillibourne JE; Tack F; Vloemans N; Boeckx A; Thambirajah S; Bonnet P; Ramaekers FC; Bornens M; Grand-Perret T
Mol Biol Cell; 2010 Feb; 21(4):547-61. PubMed ID: 20032307
[TBL] [Abstract][Full Text] [Related]
9. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
10. Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy.
Zhang X; Wei C; Liang H; Han L
Front Oncol; 2021; 11():587554. PubMed ID: 33777739
[TBL] [Abstract][Full Text] [Related]
11. SmSak, the second Polo-like kinase of the helminth parasite Schistosoma mansoni: conserved and unexpected roles in meiosis.
Long T; Vanderstraete M; Cailliau K; Morel M; Lescuyer A; Gouignard N; Grevelding CG; Browaeys E; Dissous C
PLoS One; 2012; 7(6):e40045. PubMed ID: 22768216
[TBL] [Abstract][Full Text] [Related]
12. The structure of the plk4 cryptic polo box reveals two tandem polo boxes required for centriole duplication.
Slevin LK; Nye J; Pinkerton DC; Buster DW; Rogers GC; Slep KC
Structure; 2012 Nov; 20(11):1905-17. PubMed ID: 23000383
[TBL] [Abstract][Full Text] [Related]
13. GCP6 is a substrate of Plk4 and required for centriole duplication.
Bahtz R; Seidler J; Arnold M; Haselmann-Weiss U; Antony C; Lehmann WD; Hoffmann I
J Cell Sci; 2012 Jan; 125(Pt 2):486-96. PubMed ID: 22302995
[TBL] [Abstract][Full Text] [Related]
14. Autoinhibition and relief mechanism for Polo-like kinase 4.
Klebba JE; Buster DW; McLamarrah TA; Rusan NM; Rogers GC
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):E657-66. PubMed ID: 25646492
[TBL] [Abstract][Full Text] [Related]
15. Role of Polo-like Kinases Plk1 and Plk4 in the Initiation of Centriole Duplication-Impact on Cancer.
Hoffmann I
Cells; 2022 Feb; 11(5):. PubMed ID: 35269408
[TBL] [Abstract][Full Text] [Related]
16. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
Tian X; Zhou D; Chen L; Tian Y; Zhong B; Cao Y; Dong Q; Zhou M; Yan J; Wang Y; Qiu Y; Zhang L; Li Z; Wang H; Wang D; Ying G; Zhao Q
Cell Death Dis; 2018 Jan; 9(2):54. PubMed ID: 29352113
[TBL] [Abstract][Full Text] [Related]
18. The Polo kinase Plk4 functions in centriole duplication.
Habedanck R; Stierhof YD; Wilkinson CJ; Nigg EA
Nat Cell Biol; 2005 Nov; 7(11):1140-6. PubMed ID: 16244668
[TBL] [Abstract][Full Text] [Related]
19. PIPKIγ targets to the centrosome and restrains centriole duplication.
Xu Q; Zhang Y; Xiong X; Huang Y; Salisbury JL; Hu J; Ling K
J Cell Sci; 2014 Mar; 127(Pt 6):1293-305. PubMed ID: 24434581
[TBL] [Abstract][Full Text] [Related]
20. Human Cep192 and Cep152 cooperate in Plk4 recruitment and centriole duplication.
Sonnen KF; Gabryjonczyk AM; Anselm E; Stierhof YD; Nigg EA
J Cell Sci; 2013 Jul; 126(Pt 14):3223-33. PubMed ID: 23641073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
